Clinical Expertise from Mayo Clinic at AAN 2018
CNS Demyelinating Disease (AQP4-IgG & MOG-IgG)
Testing for AQP4 and MOG antibodies allows for the most comprehensive evaluation for patients recently diagnosed with demyelinating diseases and distinguishes a spectrum of demyelinating disease from multiple sclerosis.
Mayo Clinic has developed the only fluorescence-activated cell sorting (FACS) live cell-binding assay that is currently available in the U.S. for antibody detection of AQP4 and MOG. FACS is recommended by international leaders in neuroimmunology for its increased sensitivity and specificity.
1/3of AQP4-IgG (-) NMO patients positive for MOG-IgG
Recurrent optic neuritis patients who are positive for AQP4-IgG or MOG-IgG
frequency that MOG-IgG is positive compared to AQP4-IgG
MAYO CLINIC RESEARCH IN SUPPORT OF AQP4-IGG AND MOG-IGGAQP4 Autoantibody Assay Performance in Clinical Laboratory Service Neurology, Neuroimmunology, & Neuroinflammation
- CNS Demyelinating Disease Evaluation, Serum (ID: CDS1) Test Catalog | Overview PDF
- Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum (ID: NMOFS) Test Catalog
- Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Serum (ID: MOGFS) Test Catalog | Overview PDF
Glial Fibrillary Acidic Protein (GFAP)-IgG
Available Clinically in 2018
A novel astrocytic autoantibody, glial fibrillary acidic protein (GFAP) has recently been described by Mayo Clinic as a biomarker of a relapsing autoimmune meningoencephalomyelitis that is responsive to immunotherapies. Seropositivity distinguishes autoimmune GFAP meningoencephalomyelitis from disorders commonly considered in the differential diagnosis.
40%of patients with GFAP-IgG have co-existing antibodies
GFAP-IgG is 33.33% as common as NMDA-R antibody
MAYO CLINIC RESEARCH IN SUPPORT OF GFAP-IGGAutoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis JAMA Neurology Glial Fibrillary Acidic Protein Immunoglobulin G as Biomarker of Autoimmune Astrocytopathy: Analysis of 102 Patients Annals of Neurology
Autoimmune Movement Disorder Evaluations
Autoimmune movement disorders encapsulate a large and diverse group of neurologic disorders occurring either in isolation or accompanying more diffuse autoimmune encephalitic illnesses. The full range of movement phenomena has been described and, as they often occur in adults, many of the presentations can mimic neurodegenerative disorders, such as Huntington disease.
Our comprehensive autoimmune movement disorder evaluations includes mGluR1 and DPPX antibodies.
53%of autoimmune cerebellar ataxia is paraneoplastic
of autoimmune cerebellar ataxia patients improve with immunotherapy
MAYO CLINIC RESEARCH IN SUPPORT OF AI MOVEMENT DISORDER TESTINGAutoimmune Movment Disorders: A Clinical and Laboratory Approach Current Neurology and Neuroscience Reports DPPX Potassium Channel Antibody: Frequency, Clinical Accompaniments, and Outcomes in 20 Patients Neurology Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes Neurology
FEATURED TESTS - Available Monday, April 23
Neuromuscular and Peripheral Neuropathy NGS Testing
Our targeted approach allows for optimal mutation detection and interpretation through targeted capture techniques and unique reporting methods. This process eliminates the risk of false-negative results compared to whole-exome sequencing and other capture techniques. Disease-specific mutations will not be missed.
>100xminimum depth of coverage
average depth of coverage
- Neuromuscular Genetic Panels by NGS (ID: NMPAN)
Test Catalog | Overview PDF
- Subpanels for myopathy, muscular dystrophy, congenital myopathy, metabolic myopathy, myofibrillar myopathy, distal myopathy, emery-dreifuss, rhabdomyloysis and myopathy, distal weakness, motor neuron disease, congenital myasthenic syndromes, and skeletal muscle channelopathy
- Neuromuscular Genetic Panels by NGS (ID: NMPAN) Test Catalog | Overview PDF